COVID Collaboration Planet Biotechnology is actively pursuing a COVID-19 therapeutic program through a partnership with iBio focused on an ACE2-Fc immunoadhesin. This demonstrates a proven path for co-development and potential plant-based manufacturing collaborations for COVID-19 therapies.

Plant-based Platform The company pioneered plant-made antibodies and can rapidly adapt antibody and receptor-antibody fusion products for production in non-food, greenhouse-grown plants. This platform offers a differentiating route for partners seeking faster timelines and scalable production of biologics.

Infectious Disease Focus The focus on antibodies for infectious diseases, including emerging pathogens and bio-threat agents, creates business development opportunities with pharma, biotech, biodefense, and public health programs for discovery, development, and plant-based manufacturing partnerships.

Strategic Growth Potential As a small, tightly resourced company with ongoing partnerships and revenue potential, Planet Biotechnology presents opportunities for strategic collaborations, licensing expansion, and contract development/manufacturing deals with larger industry players to accelerate growth.

Manufacturing Readiness The non-food, non-feed plant production model grown in greenhouse environments supports rapid scale-up for clinical-grade biologics, offering potential manufacturing capacity and related process development support for trials and early commercialization of plant-based therapeutics.